On September 29, 2025, Sutro Biopharma, Inc. announced a significant organizational restructuring aimed at streamlining its operations, which includes reducing workforce by about one-third and is expected to cost approximately $4.1 million to $4.3 million. This restructuring will help extend the company's funding runway until at least mid-2027 and prioritize its three preclinical ADC programs.